Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 30;16(4):e0250830. doi: 10.1371/journal.pone.0250830

Retroactivity induced operating regime transition in an enzymatic futile cycle

Akshay Parundekar 1, Ganesh A Viswanathan 1,*
Editor: Christopher Rao2
PMCID: PMC8087108  PMID: 33930059

Abstract

Activated phosphorylation-dephosphorylation biochemical reaction cycles are a class of enzymatic futile cycles. A futile cycle such as a single MAPK cascade governed by two underlying enzymatic reactions permits Hyperbolic (H), Signal transducing (ST), Threshold-hyperbolic (TH) and Ultrasensitive (U) operating regimes that characterize input-output behaviour. Retroactive signalling caused by load due to sequestration of phosphorylated or unphosphorylated form of the substrate in a single enzymatic cascade without explicit feedback can introduce two-way communication, a feature not possible otherwise. We systematically characterize the operating regimes of a futile cycle subject to retroactivity in either of the substrate forms. We demonstrate that increasing retroactivity strength, which quantifies the downstream load, can trigger five possible regime transitions. Retroactivity strength is a reflection of the fraction of the substrate sequestered by its downstream target. Remarkably, the minimum required retroactivity strength to evidence any sequestration triggered regime transition demands 23% of the substrate bound to its downstream target. This minimum retroactivity strength corresponds to the transition of the dose-response curve from ST to H regime. We show that modulation of the saturation and unsaturation levels of the enzymatic reactions by retroactivity is the fundamental mechanism governing operating regime transition.

1. Introduction

Enzymatic cascades or futile cycles consisting of phosphorylation-dephosphorylation biochemical reaction cycles, are crucial, ubiquitously conserved, building-blocks of cellular signalling networks [1, 2]. An enzymatic futile cycle employs phosphorylation and dephosphorylation reactions, respectively catalysed by kinase and phosphatase, to enable transition of a protein substrate between its two forms, namely inactive and active. Enzymatic cascades impart important properties like responsiveness, robustness, specificity onto a signalling response [3, 4], weak signal amplification [5], signal speed acceleration [6], filter out noise in signal [79]. One such well-known enzymatic cascade is the Raf/MEK/ERK MAPK cascade, a key signal amplifier and a modulator of pro-survival and pro-apoptotic signalling pathways [1012]. Aberrant functioning of this cascade has been implicated in many diseases such as cancer [13, 14]. Detailed understanding of the sustained and transient activation patterns of MAPK cascade can therefore offer useful insights in designing therapeutic strategies for combating certain diseases.

Activation behaviour of a futile cycle as a response to a stimulus of certain strength and their dynamic evolution have traditionally been characterized by systematically studying the dose-response curves permitted by the cascade [1517]. Dose-response curve or the input-output characteristic of the cycle at steady-state is a map of the abundances of the input kinase and of the active protein (output) of the cascade [18]. Based on the qualitative nature of the dose-response curve, dictated by the saturated/unsaturated state of the two enzymatic reactions, the activation behaviour of futile cycle have been classified into four distinct operating regimes, viz., Hyperbolic (H), Signal transducing (ST), Threshold-hyperbolic (TH), Ultrasensitive (U), each of which display different signal processing capabilities [18, 19]. Operating regimes of the MAPK cascades juxtaposed with patient-stratification data have recently been considered in disease prognostics [20]. Recently, a hybrid deterministic-stochastic approach constrained by experimental ensemble data was used for predicting and characterising the input-output behaviour of a single MAPK cycle. This approach revealed that the MEK-ERK cycle in PMA stimulated Jurkat-T cells could be operating in H or ST regimes depending on the strength of the stimulus [21]. A quasi-steady-state approximation Michealis-Menten model [22] employed in the hybrid approach [21] could not explain the observed transition of the regime effected by merely changing the stimulus strength. A question thus arises as to what could be the mechanism that may govern the observed operating regime transition under steady-state conditions.

When Raf/MEK/ERK enzymatic cascades is modelled without an explicit feedback, signal flow is usually described as a one-way communication, that is, going from upstream to downstream of the cascade [23]. However, recently, a new type of signalling called retroactive signalling, which is caused by the presence of a downstream load, has been considered [2428]. This phenomenon occurs due to the possibility that the futile cycles are coupled with another downstream cascade/substrate. Either or both forms of the protein involved in a futile cycle could be sequestered by another substrate which could be a part of another cascade or simply by a DNA to which one of the forms of the protein is sequestered [2426, 29, 30]. In the case of Raf/MEK/ERK, the sequestration of the phosphorylated ERK could result in a retroactivity in the cascade. It has been shown experimentally that retroactivity indeed plays a role in the behaviour of MAPK cascades and other signalling pathways [24, 3135]. Presence of retroactivity in enzymatic cascades has been suggested to predict a more realistic drug-response curve, that is, an input-output behaviour [30].

Inclusion of sequestration effects, which is known to affect the enzymatic futile cycle behaviour [24, 35] may cause a shift in the operating regimes at deterministic level [30]. It is thus likely that incorporating the presence of retroactive signalling might predict the stimulus-strength dependent operating regime transition. In this study, we consider systematically characterising the effect of the presence of substrate or product retroactivity on the operating regimes of MEK/ERK enzymatic cascade. Specifically, we show that strength of the retroactive signalling can modulate the nature of the operating regimes and can permit operating regime transitions.

2. Mathematical model of a futile cycle with retroactive signalling

We consider an enzymatic futile cycle with retroactive signalling wherein an enzyme catalysed transition between inactive (M) and active (Mp) forms of the protein substrate occurs (Fig 1). We assume that both forms of the proteins M and Mp may be sequestered reversibly, respectively by downstream targets S1 and S2 and thereby incorporate retroactivity in the cascade (Fig 1).

Fig 1. Enzymatic futile cycle with retroactivity.

Fig 1

M and Mp are the inactive and active forms of the protein substrate. Kinase E and phosphatase P, respectively are the enzymes for the phosphorylation and dephosphorylation biochemical reactions. While S1 and S2 are the downstream targets, respectively of M and Mp, MS1 and MpS2 are the corresponding sequestered complexes.

The biochemical reactions corresponding to the enzymatic cascade in Fig 1 are

E+MEME+Mp [1]
P+MpPMpP+M [2]

and those capturing the downstream sequestration steps are

M+S1MS1 [3]
Mp+S2MpS2 [4]

We assume quasi-steady state approximation (QSSA) for the two intermediate complexes in Eq (1) and (2), and for the two complexes formed by sequestration reactions (Eqs 3 and 4). Upon employing QSSA, the dynamics of dimensionless concentration of Mp, m¯ = mp/mt where mt is the total protein substrate, dictated by the biochemical reactions in Eqs (14) is given by the mathematical kinetic model

dm¯dt=1mt(Rp(et,λ,m¯)Rd(α,m¯))=kfet(1m¯)K1(1+λ)+mt(1m¯)krptm¯K2(1+α)+mtm¯ [5]

where, kf, and kr, respectively are the forward and reverse catalytic rate constants, et and pt, respectively capture the total concentrations of kinase E and phosphatase P. K1 and K2 are the Michaelis-Menten (MM) constants for the forward and backward enzymatic reactions, respectively [22, 36]. Rp(et, λ, m¯) and Rd(α = 0, m¯), respectively capture the phosphorylation and dephosphorylation reaction rates. Assuming the equilibrium constants for binding of M and Mp are equal, the retroactivity strengths for sequestration of M and Mp, respectively are given by

λ=s1/Kdandα=s2/Kd [6]

where s1 and s2 are the concentrations of species S1 and S2, respectively and Kd is the equilibrium constant corresponding to the sequestration reactions. A detailed derivation of Eq (5) from the full model capturing the dynamics of the biochemical reactions (Eqs 14) along with the definition of associated MM constants is in S1 Appendix. Note that the effect of retroactivity of either M or Mp or both on the phosphorylation (first term in the right hand side or rhs) and dephosphorylation (second term in rhs) rates in Eq (5) is quantitatively accounted for by scaling the MM constants K1 and K2 with non-zero (positive) values of λ and α, respectively.

Upon setting the left hand side or lhs to zero and solving analytically the resulting quadratic equation, we find the steady-state solution of Eq (5) as

m¯=mpmt={b+b24(kfet/krpt)(1kfet/krpt)(K2(1+α)/mt)2(kfet/krpt1),kfetkrpt111+K1(1+λ)/K2(1+α),kfetkrpt=1 [7]

where, b=(kfet/krpt1)+(K2(1+α)/mt)(kfet/krpt)+K1(1+λ)/mt. In S1 Text, we show that this steady-state solution (Eq 7) matches with that of the full model (Eq [AI.1-AI.4] and [AI.5]), for all range of values assigned to the parameters. Dose-response curve m¯p (K¯1, K¯2, et) of the futile cycle with (or without) retroactivity is essentially the locus of the relationship between m¯p and et, with all other parameters fixed [19, 21]. Note that m¯p can be drawn using Eq (7) for (a) without retroactivity by setting α = λ = 0, (b) with retroactivity only in M by setting α = 0, λ > 0, (c) with retroactivity only in Mp by setting α>0, λ = 0 and (d) with retroactivity in both M and Mp by setting α>0, λ>0 [24]. Since introduction of retroactivity tantamount to proportional scaling of the MM constants (Eq 5), for the sake of brevity, we define effective MM constants K¯1 = K1 (1+λ) and K¯2 = K2 (1+ α) which when λ or α set to zero will correspond to the case of absence of retroactivity in M or Mp, respectively. Dose-response curve m¯p can be classified into four distinct operating regimes, viz., H, ST, TH and U. Each of these regimes have a representative dose-response curve referred to as nominal profile. These four nominal profiles correspond to the four combinations of the saturated or unsaturated states of the two enzymatic reactions, viz., phosphorylation and dephosphorylation reactions of the futile cycle, as summarized in Table 1. An enzymatic reaction is considered saturated when most of the enzyme is bound to the substrate. The saturated state of the reaction occurs when the corresponding Michaelis-Menten constant is significantly smaller than the substrate concentration. K¯1n, K¯2n, where superscript n = H, ST, TH and U, used for arriving at the four nominal profiles of the futile cycle are in Table 1. As a ready reckoner, we present in Fig 2 the nominal dose-response curves m¯pn with n = H, ST, TH, U for the four regimes. Parameters besides K¯1n,K¯2n used for arriving at these curves are kr = kf = 0.01s-1, pt = 200nM and mt = 1000nM [18, 21]. Unless otherwise explicitly stated, these parameter values specified are employed for the rest of the study.

Table 1. The nature of the state of the two biochemical reactions corresponding to four operating regimes.

Regime ST H TH U
Phosphorylation reaction Saturated Unsaturated Unsaturated Saturated
Dephosphorylation reaction Unsaturated Unsaturated Saturated Saturated
K¯1n,K¯2n 10,10000 10000,10000 10000,10  10,10

Michaelis-Menten constants K¯1n,K¯2n used to arrive at the nominal profiles of the four regimes [18, 21].

Fig 2.

Fig 2

Schematic showing the steady-state dose response curve corresponding to the nominal profiles of (A) Hyperbolic (m¯pH), (B) Signal transducing (m¯pST), (C) Threshold hyperbolic (m¯pTH), (D) Ultrasensitive (m¯pU). The conditions employed for simulating these dose-response curves are in Table 1.

While hyperbolic response of the futile cycle is robust to fluctuations and can transmit signals in a broad range of amplitudes [37], signal transducing (ST) regime exhibiting a linear response is amenable for signalling involving graded stimuli. In the threshold-hyperbolic regime, the response of the futile cycle occurs only if the input is above the threshold, after which it increases hyperbolically [38]. Ultrasensitive (U) regime permits amplification of a small signal near the threshold which biological systems take advantage of [39]. As a reference, we employ the nominal profiles corresponding to the case wherein retroactivity is absent.

A dose-response curve is placed in one of the four regimes by contrasting the corresponding m¯p (K¯1, K¯2, et) with m¯pn(K¯1n,K¯2n,et)=mpn(K¯1n,K¯2n,et)/mt, where superscript n = H, ST, TH, U indicates regime-specific nominal profile (Methods). This approach has been suggested by Gomez-Uribe et al. [18] and adopted in several recent studies [21, 40].

3. Results

3.1 Retroactivity impacts operating regimes

In order to study the effect of retroactivity on the dose-response curve, we adopt the same strategy prescribed by Gomez-Uribe et al. [18] to characterize the operating regimes in the presence of a downstream load on M or Mp. We limit the scope of this study to the presence of retroactivity in either M or Mp. Systematic characterization reported here, without loss of generalization, can be used for the case where retroactivity may be present in both M and Mp, simultaneously.

In order to assess if retroactivity impacts the nature of the operating regime for a certain set of parameters, we consider a dose-response curve in the U regime in the absence of retroactivity (α = λ = 0), when (K¯1 (0), K¯2 (0)) = (K1, K2) = (7,70). Fig 3A shows this dose-response curve (solid yellow) contrasted against the nominal profile for U regime (dashed blue), included from Fig 2D for ease of comparison, used for identifying the regime to which it belongs to. Introduction of retroactivity in Mp with a strength of α = 27 (and λ = 0) resulting in (K¯1 (0), K¯2 (27) = (7,1960)) causes shifting of the dose-response curve (solid purple curve in Fig 3A) to the left. m¯p for case of α = 27 belongs to the ST regime indicating the possibility of retroactivity induced transition of operating regimes. (For the sake of comparison, we present m¯pST (dashed red curve) from Fig 2B in Fig 3A). We further show that introduction of (a) retroactivity in Mp can induce regime transition from H at K¯1(0), K¯2 (0) = (389,751) to ST regime at (K¯1(0), K¯2(1.5) = (389,1878) (Fig 3B) and (b) retroactivity in M can induce operating regime transition from ST to H (S1 Text). Given that the presence of a downstream load can cause a regime shift, we ask a question as to what are the other possible transitions in the presence of retroactivity. The primary goal of this study is to systematically understand the effect of retroactivity in M or Mp on the operating regimes.

Fig 3.

Fig 3

Retroactivity in Mp inducing operating regime transition from (A) U at K¯1 (λ = 0) = 7, K¯2(α = 0) = 70 to ST at (K¯1(0), K¯2(27)) = (7,1960) and (B) H at (K¯1(λ = 0) = 389, K¯2(α = 0) = 751) to ST at (K¯1 (0),K¯2 (15)) = (389,12016). Inset: Zoom in of the dose-response curves. For ease of comparison, the nominal profiles m¯pU and m¯pST from Fig 2D and 2B, respectively are included in (A). Similarly, m¯pH and m¯pST from Fig 2A and 2B, respectively are included in (B). Parameters (K¯1(0), K¯2(0)) used for simulating the nominal profiles are in Table 1.

3.2 Retroactivity strength dictates nature of regime transition

Retroactivity introduces a scaling for the Michaelis-Menten constants (Eq 5) and thereby affects the steady-state behaviour (Eq 7). As a result, in order to study the effect of retroactivity strength on the operating regimes, it is sufficient to understand how the parameter space of effective Michaelis-Menten constants K¯1 = K1(1+λ) and K¯2 = K2(1+α) is partitioned into different input-output behaviours. Note that replacing K1(1+λ) and K2(1+α) in Eq (7) respectively with K¯1 and K¯2 makes the retroactivity embedded steady-state solution form similar to that of an isolated enzymatic cascade. Thus, knowledge of the boundaries of the different operating regimes in the planes of K¯1 and K¯2 could be directly used to decipher the effect of retroactivity on the dose-response curves exhibiting a certain input-output characteristic by varying λ or α.

Next, we implemented an optimization problem to delineate the parameter space (K¯1, K¯2) corresponding to the four distinct operating regimes. For the ease of constructing the map, assuming α = λ = 0, for an operating regime, after specifying a K¯1 we identified K¯2 by increasing retroactivity strength α such that the candidate dose-response curve m¯pc(K¯1,K¯2,et) satisfied the relative distance criterion

dc(K¯1,K¯2,n)=m¯pcm¯pnmaxcm¯pcm¯pn=0.1 [8]

for all n = H, ST, TH, and U. (Note that superscript c in m¯pc(K¯1,K¯2,et) refers to a candidate.) This criterion is based on the metric suggested by Gomez-Uribe et al. [18] and recently used in Parundekar et al. [21]. In the metric introduced by Gomez-Uribe et al. [Gomez-Uribe et al.], the total substrate concentration is used as scaling. The predictions are therefore a function of the total substrate concentration itself. However, the basis for finding the distance from the nominal curves introduced by Parundekar et al. [21] constitutes scaling using the maximum regime-specific distance from its nominal profile. This metric offers advantages such as scaling being a self-learned parameter, relative distance estimation that is not biased by the system parameters. Next, we briefly describe the procedure adopted for estimating dc(K¯1, K¯2, n).

Every candidate dose-response curve will have four distances, each corresponding to a comparison with four regime-specific nominal profiles (Fig 2). Finding dc(K¯1, K¯2, n) objectively for a dose-response curve requires estimation of maxcm¯pcm¯pn in Eq (8) a priori. However, the information about the regime to which a candidate m¯pc belongs to is unavailable. In order to address this, we first created a randomly chosen parameter-profile database containing 140000 sets of (K¯1, K¯2) sampled using stratified random sampling (Methods) across five orders of magnitude range each tagged to its dose-response curve m¯p. (Note that the maximum possible value that an element in m¯p can take is 1 [21].) Next, we performed an optimization (Methods) for finding K¯2 that satisfies Eq (8) and its corresponding m¯p. As an example, consider finding the boundaries of H regime by setting n = H in Eq (8). In the five-orders of magnitude range considered, finding (K¯1,K¯2) whose corresponding m¯p satisfied Eq (8) enabled identifying the boundary for the H regime in the planes of effective Michaelis-Menten constants (Fig 4, orange lines). Note that the dashed lines correspond to those (K¯1, K¯2) on the boundary sourced directly from the database. We repeated the entire procedure to find the boundaries corresponding to U (blue), ST (yellow), and TH (red) regimes (Fig 4). We note that upper boundary of the ST regime is an exception. While constructing the upper boundary for ST regime, we observed that the dose-response curve is insensitive to K¯2 beyond a certain limit after which K¯2 has no effect on dc(K¯1, K¯2, ST). Therefore, for representation purposes, we fixed the upper boundary for ST (yellow) at dc(K¯1,K¯2,ST)0.02 by accordingly modifying Eq 8. Note that as a direct consequence the dose-response curves well beyond the upper boundary of ST will belong to the signal-transducing regime. Metric adopted in Eq 8 by and large separates the regions where these four regimes exist. We note that the underlying model assumptions and the metric used by Gomez-Uribe et al. [18] are different as compared to those considered here. These differences could be attributed to the range for the operating regimes in Fig 4 not being same as those reported in [18].

Fig 4. Boundaries of the four operating regimes hyperbolic (H, blue), signal transducing (ST, green), threshold-hyperbolic (TH, red), and ultrasensitive (U, yellow) in the planes of K¯1 and K¯2 for λ = α = 0.

Fig 4

All boundaries of each of the regimes except the upper boundary of ST satisfy the relative distance criterion in Eq (8). For the case of upper boundary of ST the rhs of Eq (11) was set to 0.02. (K¯1, K¯2) on the dotted lines extending the solid line boundaries were sourced directly from the database. While dose-response curves corresponding to parameter sets at green dots A and B were used as example of transition from U to TH regime, those curves at C and D of transition from H to ST.

Since changing retroactivity strength can independently modulate the Michaelis-Menten constants, manipulating K¯1 or K¯2 or both could cause a shift in the characteristic input-output behaviour. Specifically, by increasing the strength of the load in M causing proportional change in K¯1 while keeping K¯2 constant, a dose-response curve in U or ST, respectively can shift to TH or H. For example, m¯p(10,10) in U regime (Fig 4, point A) would shift to TH (Fig 4, point B) upon increasing K¯1 to 10000. Similarly, while maintaining K¯1 constant, an increase in the retroactivity strength in Mp leading to proportional change in K¯2 could lead to four other possible regime transitions, viz., U to ST, TH to H or ST, and H to ST. m¯p (6000,6000) in H regime (Fig 4, point C) transitions into ST regime (Fig 4, point D) when K¯2 is scaled to 60000. For a given source profile specified by a certain (K¯1, K¯2) with no retroactivity either in M or Mp, while maintaining K¯1 or K¯2 constant, the minimum load λmin or αmin, respectively required for inducing a regime transition is sensitive to the chosen K¯1(0) or K¯2(0) (S1 Text). This sensitivity analysis showed the minimum load needed for any regime transition to occur is 0.3. This minimum corresponds to transition of ST at (K¯1(λ = 0), K¯2(α = 0)) = (8205,28160) to H regime due to retroactivity in M with λmin being 0.3. λmin = 0.3 translates to (ms1/(mtmp)) = λmin/(1+ λmin) = 0.23 indicating that 23% of the unphosphorylated substrate sequestered by downstream target is needed for inducing this transition.

3.3 Saturation level of the two enzymatic reactions governs the retroactivity induced regime transition

Since the dose-response curve m¯p explicitly depends on K¯1(λ) and K¯2 (α) (Eq 7), understanding how load strength λ or α influences the input-output behaviour may offer useful insights into what causes retroactivity driven operating regime transition. In order to assess the regime-specific impact of retroactivity on the input-output behaviour, we systematically analyse the dose-response curves and the associated sensitivity with respect to retroactivity strengths λ and α.

The sensitivity of m¯ with respect to retroactivity strength λ and α, respectively are quantitatively captured by

dm¯dλ=(dm¯dK¯1)(dK¯1dλ)=(dm¯dK¯1)K¯1(0)=(dm¯dK¯1)K1 [9]

and

dm¯dα=(dm¯dK¯2)(dK¯2dα)=(dm¯dK¯2)K¯2(0)=(dm¯dK¯2)K2 [10]

for a finite (non-zero) downstream load. Detailed expressions of these are in S2 Appendix. Eqs 9 and 10 show that the presence of retroactivity in M or Mp introduces a constant scaling of K¯1(0) = K1 or K¯2(0) = K2, respectively to the sensitivity with respect to the corresponding Michaelis-Menten constant. In the sub-sections below, we present the sensitivity effects due to modulation of retroactivity corresponding to either M or Mp for these five transitions and distil out the underlying causal mechanism. For the case of substrate or product retroactivity modulation, we first fix (K¯1(0) = K1, K¯2(0) = K2) in a certain regime with no retroactivity and then increasing λ or α, respectively and track the ensuing regime transition.

3.3.1 U to TH transition due to retroactivity in M

The dose-response curves obtained by starting from U regime for (K¯1(λ = 0) = K1, K¯2(α = 0) = K2) = (9nM,9nM) with dc(9nM,9nM, U) = 0.013 and transitioning into TH regime by changing λ is shown in Fig 5A. Note that while α = 0, increasing λ leads to a proportional scaling of K¯1(λ). Introduction of retroactivity causes changes to the extent of ultrasensitive nature of the dose-response curves. This extent of ultrasensitive nature in the presence of retroactivity can be quantified via the half-maximal response given by

S50=krptkfEC50=K¯2(α)+0.5K¯1(λ)+0.5=K2(1+α)+0.5K1(1+λ)+0.5 [11]

which uniquely specifies the dose-response curve’s EC50, that is, et at which m¯ = 0.5 [24]. Note that when λ = α = 0, Eq (11) reduces to the response defined in Goldbeter and Koshland [19]. As the dose-response curve transits from U to TH, the EC50 increases from 200 to 4400 for the range of λ considered (S1.3 Fig in S1 Text). Note that EC50 increases linearly with the retroactivity strength λ (Eq 11). Moreover, Fig 5A also reveals that an increase in load shifts the dose-response curve by simultaneously enlarging the curve’s base resulting in a threshold and also the curvature eventually leading to a TH input-output behavior. Next, we elucidate what causes the observed U to TH transition.

Fig 5.

Fig 5

Effect of retroactivity strength on the operating regimes and the associated sensitivity for (i) U to TH, (ii) U to ST, and (iii) H to ST transitions. While panel (i) corresponds to effects due to load on M quantified by λ, panel (ii) and (iii) captures those due to load on Mp quantified by α. Dependence of dose-response curves on the load corresponding to (i), (ii) and (iii) are in (A), (D) and (G), respectively. Sensitivity of steady-state level for different retroactivity strengths for (i), (ii), and (iii) are in (B), (E) and (H), respectively. Sensitivity curves in (B) was estimated using Eq (9), Eq (10) was employed for those in (E) and (H). While rate-balance plot showing the effect of retroactivity strength on modulation of steady-state levels corresponding to (i) at et = 1000nM is in (C), that for (ii) and (iii) at et = 150nM are in (F) and (I), respectively. Colorbar in each of the panels display the retroactivity strengths. Dotted line in (A), (B) and (C) in panel (i) corresponds to the dose-response, sensitivity and Rd(λ) curves, respectively at the transition where λ = 960. Dotted line in panels (ii) and (iii) captured these curves at the corresponding transition where α = 9.44 and α = 5, respectively.

In Fig 5B, we show the modulation of sensitivity (Eq 9) by λ and et. An increase in λ in dose-response curve m¯p(K¯1(λ), K¯2(0), et) leads to a decreased negative sensitivity. This shift in peak is correlated to the corresponding increase in the EC50 (S1.3 Fig in S1 Text), as has also been reported in Ventura et al. [24]. This behaviour is dictated by the steady-state levels of Mp (Eq 7), which is a balance between the phosphorylation and dephosphorylation rate terms in the rhs of Eq 6 for a given λ and et. Insights into the effect of λ on m¯ can be deciphered from the nature of relative variation of these two rates, which we discuss next.

In Fig 5C, we present the rate-balance plot consisting of the rate curves of the phosphorylation reaction Rp(et = 1000 nM, λ, m¯) for different λ and of the dephosphorylation reaction Rd(α = 0, m¯). Note that Rp and Rd are the rates of the two enzymatic reactions defined in Eq (5). The nature of an enzymatic reaction being saturated, that is, all enzymes bound to its substrate, is specified by the range of m¯ for which the corresponding rate does not change significantly. Therefore a sufficient proportional increase in K¯1(λ) due to λ can lead to Rp exhibiting a linear dependence on m¯ in a certain range. The nature of the phosphorylation reaction is unsaturated in this range of m¯. In the U regime, both Rp(1000 nM, λ = 0, m¯) (Fig 5C, black) and Rd (0, m¯) (Fig 5C, dashed) curves are predominantly saturated. For the chosen et, at λ = 0, the intersection occurs in the region where Rp is not saturated and Rd is saturated, leading to m¯1. Increasing λ forces the phosphorylation reaction (Rp curve) to gradually become predominantly unsaturated (Fig 5C). The extent of this unsaturation introduced underlies the shift in the intersection point of the rate curves in the direction of decreasing m¯. Thus, increasing λ causes significant decrease in the steady-state levels m¯ (Fig 5C). This decrease explains the gradual change in the steady-state levels at et = 1000 nM in the different dose-response curves in Fig 5A. Moreover, this decrease results in a significant change in the sensitivity (Fig 5B). At λ = 960, due to sufficient levels of unsaturation, the operating regime transits into the TH regime, which is characterized by the phosphorylation and dephosphorylation reactions, respectively being unsaturated and saturated. At the transition, the relative distance from the TH nominal profile m¯pTH is dc(K¯1(960) = 8649, K¯2 = 9,TH) = 0.0833.

3.3.2 U to ST transition due to retroactivity in Mp

For (K¯1(λ = 0) = K1, K¯2(α = 0) = K2) = (7nM,70nM), the effect of dose-response curves on the retroactivity strength α is in Fig 5D. The dose-response curve when α = 0 (Fig 5D, black) with a dt(7nM,70nM, U) = 0.049 and EC50 of 178 nM, at α = 9.44 shifted to the ST regime with a dt(K¯1(0)=7,K¯2(9.44)731,ST)=0.0965, with the EC50 being 82 nM (S1.3 Fig in S1 Text). We next discuss what causes this regime transition.

Fig 5E shows that an increase in the retroactivity strength α in dose-response curve m¯p (K¯1 (0), K¯2(α), et) while maintaining λ = 0 causes reduction in the (positive) sensitivity. The rate-balance analysis at et = 150nM shows that when α = 0, the intersection of the two rate-curves occurs in the region where the phosphorylation reaction is near saturation (Fig 5F). Note that the Rd curve is predominantly saturated when α = 0. An increase in α, that is, K¯2(α) shifts the nature of Rd curve to predominantly unsaturated. This shift causes the intersection, that is, steady-state level, to increase from 0.2 at α = 0 to 0.99 at α = 18. Therefore, increasing the load leads to an increase in the steady-state level depending on the extent of the unsaturation evidenced by the dephosphorylation reaction. This shift in the steady-state level forces the dose-response curve to move into the ST operating regime.

3.3.3 H to ST transition due to retroactivity Mp

For (K¯1(λ = 0) = K1, K¯2(α = 0) = K2) = (3000nM,3000nM), the effect of dose-response curves on the retroactivity strength α is in Fig 5G. At α = 0, the dose-response curve belonged to the H regime with a dc(3000nM,3000nM, H) = 0.014. Upon increasing α to 5, dose-response curve transitions to ST operating regime with dc(K¯1(0)=3000,K¯2(5)18000,ST)=0.08. EC50 for the dose-response curves changes from 200nM to ~38nM (S1.3 Fig in S1 Text). Increase in the load causes a decrease in the sensitivity. The rate-balance plot for et = 150nM shows that both phosphorylation and dephosphorylation reactions are predominantly unsaturated in the H regime for α = 0. Upon increasing the load, while the dephosphorylation reaction continues to remain unsaturated, the rate curve shows a slowed-down response to increase in m¯, that is, reduction of the slope of the Rd curve. This reduction causes a shift in the intersection of the rate-curves to a larger substrate concentration. For e.g., for et = 150nM, the steady-state level at α = 0 and 20 are 0.42 and 0.94, respectively. Thus, the dose-response curve transitioning from the H to ST is essentially caused by this reduction in the slope of the Rd curve with increase in the retroactivity strength in Mp.

3.3.4 ST to H and TH to H transitions due to retroactivity M and Mp

In Fig 6, we show the dose-response curves capturing the regime transition from ST to H and TH to H driven by load in M and Mp, respectively. For the case of ST to H transition (Fig 6A), at (K¯1(λ = 0) = K1, K¯2(α = 0) = K2) = (9 nM,9000nM), the dose-response curve has an EC50 of ~11 with a dc(9,9000,ST) = 0.003. With an increase in the retroactivity strength λ in M, the EC50 increases and at λ = 400, the dose-response curves achieved corresponds to the H regime with a dc(K¯1(400) = 3609, K¯2 = 9000,TH) = 0.092 and EC50 of 86.5 (S1.3 Fig in S1 Text). Sensitivity analysis and rate-balance plot at et = 12nM show that while dephosphorylation reaction is unsaturated, an increase in λ the phosphorylation reaction transitions from predominantly saturated to unsaturated state and thereby, driving the regime transition (S1.4 Fig in S1 Text).

Fig 6.

Fig 6

Dose-response curves capturing the retroactivity driven transition of operating regimes from (A) ST to H and (B) TH to H. Colorbar displays the retroactivity strength corresponding to the dose-response curves. Dotted lines in (A) and (B), respectively correspond to the retroactivity strength λ = 400 and α = 578 at which the regime transition occurs.

The dose-response curve at (K¯1(λ = 0) = K1, K¯2(α = 0) = K2) = (9000 nM,9 nM) belonging to the TH regime with dc(9000,9,TH) = 0.05 transitions into H regime with increase in load α from 0 to 578 (Fig 6B). The dc(K¯1(0) = 9000, K¯2(578) = 5211,H) = 0.07. Sensitivity and rate-balance plots at et = 3000 nM suggests that regime transition is caused by the phosphorylation reaction being unsaturated and the dephosphorylation reaction shifting from being predominantly saturated at α = 0 to primarily unsaturated with increasing α (S1.5 Fig in S1 Text).

4. Discussion and conclusion

Input-output behaviour of an activated enzymatic futile cycle has been studied extensively due to its ability to orchestrate cell fate in direct and indirect context-dependent manners [2, 14, 21]. Michealis-Menten constants (MM) dictated saturated/unsaturated state of the two enzymatic reactions facilitates placing steady-state dose-response curves of a futile cycle into Signal transducing (ST), Hyperbolic (H), Threshold hyperbolic (TH) and Ultrasensitive (U) operating regimes (Fig 2) [18]. The unphosphorylated (M) and phosphorylated (Mp) forms of the protein substrate involved in the futile cycle can be sequestered by respective downstream targets. The sequestration dictated load or retroactivity on the upstream protein levels introduces a two-way signal flow permitting modulation of the steady-state behaviour [24, 26]. In this study, we systematically show that the presence of retroactivity in M or Mp can shift the input-output behaviour from one operating regime to another by modulating the level of saturation or unsaturation of the enzymatic reactions. In particular, we demonstrate five possible transitions: (a) U to TH and ST to H caused by retroactivity in M and (b) U to ST, TH to H, and H to ST by that in Mp.

Using a quasi-steady state approximated model of the futile cycle with retroactivity, we systematically identified the MM constants’ range that permit four distinct operating regimes in the presence of retroactive signalling (Fig 4). Surprisingly, the minimum retroactivity strength needed for inducing any transition is 0.3 which translates to 23% of the substrate bound to its target. For this minimum retroactivity strength of 0.3, dose-response curve at (K¯1(λ = 0), K¯2(α = 0)) = (8205,28160) belonging to ST regime transitions into H regime. Several downstream targets that could sequester proteins in MAPK cascades have been reported [35]. Thus, while analysing such a behaviour in a futile cycle using experimental data, ignoring the hidden retroactive signalling effect, however small, could lead to an incorrect prediction of the underlying operating regime.

While in this study we only considered increasing the retroactivity strength to trigger a regime transition, in principle, if downstream sequestrations were already present, its strength can be decreased too. Decreasing the retroactivity strength can predict five other transitions that are essentially the reverse of those analysed in this study. Further, simultaneous increase (decrease) of the retroactivity strengths in M and Mp can lead to a transition from U to H (H to U). Thus, the operating regime boundaries reported in Fig 4 permits prediction of all 12 possible regime transitions. We further note that the U and H regimes have a slight overlap in the (K¯1, K¯2) space. Our study indicates that recent experimental observations that a stimulus-strength dependent shift in the operating regimes is possible in a single MAPK cascade if the stimulus concentration change could cause retroactivity induced regime transition [21].

Using sensitivity and rate-balance analysis, we demonstrated that modulation of the saturation or unsaturation levels of the two enzymatic reactions by changing the retroactivity strength is the fundamental reason for the operating regime transition. In particular, we show that increase in retroactivity (a) in M leads to increasing unsaturation in the phosphorylation reaction and (b) in Mp makes dephosphorylation reaction more unsaturated (Fig 5, S1.4 and S1.5 Figs in S1 Text). This is due to the fact that the steady-state level of Mp, the active form, is sensitive to changes in the retroactivity strength. While increasing the strength of retroactivity in M causes a decrease in the (negative) sensitivity of the steady-state level, that in Mp leads to marked reduction in the (positive) sensitivity. This sensitivity to retroactive signalling can be capitalized upon to modulate the nature of response of the futile cycle. Synthetic biology tools are becoming available for tweaking the binding sites of targets to which the protein substrate, active/inactive forms may bind and thereby enabling control of the extent of sequestration [41, 42]. The nature of sensitivity effect that retroactive signalling bestows on the steady-state levels demonstrated in this study can be of immense value for precise engineering of a cell to control and modulate the input-output behaviour.

5. Methods

5.1 Regime identification

The regime that a dose-response curve m¯p belongs to is identified by contrasting it with the four nominal profiles m¯pn(K¯1n,K¯2n,et) where superscript n = H, ST, TH, U. The dose-response curve m¯p is ascribed to a certain regime H, ST, TH, or U if the relative distance between m¯p and the corresponding nominal profile is within 10%.

5.2 Stratified random sampling

The two stratification cut-off points were chosen. While choosing these cut-off points, (a) 60000 samples were chosen in the (0<K1<1600, 0<K2<1600) and (b) 10000 samples each in the range (0<K1<50, 0<K2<10000) and (0<K1<10000, 0<K2<50) were chosen [21]. In both these cases uniform distribution was used for sampling. Samples corresponding to either one or both reactions being saturated was at least 10% more than that for the case where both reactions were unsaturated.

5.3 Optimization for finding operating regime boundaries

The boundary for a specific regime was obtained by seeking K¯2 that satisfied the objective function in Eq (8) solved using nonlinear optimization function “fmincon” implemented in Matlab® [43]. A tolerance of 1e-6 was set as convergence criteria to the optimization problem. Optimizer convergence was sluggish in the presence of steep gradients and in these cases, the (K¯1, K¯2) samples from the database that satisfied Eq (8) was used.

Supporting information

S1 Text

S1.1- Steady-state solution of the full model. S1.2- Dose-response curve transition from Signal-Transducing to Hyperbolic regime induced by substrate retroactivity. S1.3- Minimum retroactivity strength required to transition from one regime to another. S1.4- Effect of retroactivity strength on EC50 during different regime transitions. S1.5-Sensitivity and rate balance analysis to investigate retroactivity induced ST to H and TH to H regime transitions.

(PDF)

S1 Graphical abstract

(TIFF)

S1 Appendix. Derivation of the mathematical kinetic model.

(DOCX)

S2 Appendix. Sensitivity of steady-state level to retroactivity strength.

(DOCX)

Acknowledgments

We acknowledge the DBT-Pan IIT Center for Bioenergy, IIT Bombay for an access to the high-performance computing facility.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This study was supported by Science and Engineering Research Board, Department of Science and Technology, Government of India (MTR/2020/000589 and CRG/2020/002672) for funding this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79(1):143–80. 10.1152/physrev.1999.79.1.143 [DOI] [PubMed] [Google Scholar]
  • 2.Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40. 10.1038/35065000 [DOI] [PubMed] [Google Scholar]
  • 3.Saurin AT. Kinase and Phosphatase Cross-Talk at the Kinetochore. Frontiers in Cell and Developmental Biology. Vol 6, 2018. p. 62. 10.3389/fcell.2018.00062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kleiman LB, Maiwald T, Conzelmann H, Lauffenburger DA, Sorger PK. Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell. 2011. September;43(5):723–37. 10.1016/j.molcel.2011.07.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Blüthgen N, Bruggeman FJ, Legewie S, Herzel H, Westerhoff H V, Kholodenko BN. Effects of sequestration on signal transduction cascades. FEBS J. 2006;273(5):895–906. 10.1111/j.1742-4658.2006.05105.x [DOI] [PubMed] [Google Scholar]
  • 6.Ortega F, Acerenza L, Westerhoff H V, Mas F, Cascante M. Product dependence and bifunctionality compromise the ultrasensitivity of signal transduction cascades. Proc Natl Acad Sci. 2002;99(3):1170–5. 10.1073/pnas.022267399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Thattai M, Van Oudenaarden A. Intrinsic noise in gene regulatory networks. Proc Natl Acad Sci. 2001;98(15):8614–9. 10.1073/pnas.151588598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dhananjaneyulu V, Nanda Sagar VP, Kumar G, Viswanathan GA. Noise Propagation in Two-Step Series MAPK Cascade. PLoS One. 2012;7(5):35958. 10.1371/journal.pone.0035958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Baraskar AA, Deb A, Viswanathan GA. Noise Propagation in Series Enzymatic Cascades. IFAC Proc Vol. 2013;46(31):89–94. [Google Scholar]
  • 10.Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft C V, et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog. 1999. October;26(2):119–29. [DOI] [PubMed] [Google Scholar]
  • 11.Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor‐κB signaling. Int J cancer. 2004;111(5):679–92. 10.1002/ijc.20333 [DOI] [PubMed] [Google Scholar]
  • 12.Yang J, Li G, Zhang K. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. Biomed Pharmacother. 2016. December;84:1078–87. 10.1016/j.biopha.2016.10.028 [DOI] [PubMed] [Google Scholar]
  • 13.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. 10.1016/j.cell.2011.02.013 [DOI] [PubMed] [Google Scholar]
  • 14.Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 2007. May 14;26(22):3097–9. 10.1038/sj.onc.1210395 [DOI] [PubMed] [Google Scholar]
  • 15.Santos SDM, Verveer PJ, Bastiaens PIH. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 2007. March 18;9(3):324–30. 10.1038/ncb1543 [DOI] [PubMed] [Google Scholar]
  • 16.Frank SA. Input-output relations in biological systems: measurement, information and the Hill equation. Biol Direct. 2013;8(1):31. 10.1186/1745-6150-8-31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sepulchre J-A, Merajver SD, Ventura AC. Retroactive signaling in short signaling pathways. PLoS One. 2012;7(7):e40806. 10.1371/journal.pone.0040806 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gomez-Uribe C, Verghese GC, Mirny L a. Operating regimes of signaling cycles: statics, dynamics, and noise filtering. PLoS Comput Biol 2007. Dec;3(12):e246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Goldbeter A, Koshland DE Jr. An amplified sensitivity arising from covalent modification in biological systems. Proc Natl Acad Sci U S A 1981. November;78(11):6840–4. 10.1073/pnas.78.11.6840 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, et al. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal. 2015;8(408):ra130–ra130. 10.1126/scisignal.aab0990 [DOI] [PubMed] [Google Scholar]
  • 21.Parundekar A, Kalantre G, Khadpekar A, Viswanathan GA. Operating regimes in a single enzymatic cascade at ensemble-level. PLoS One. 2019;14(8). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Michaelis L, Menten ML. aDie Kinetik der Invertinwirkung, o Biochem. z. 1913;49:333–69 (Johnson KA, Goody RS. The original Michaelis constant: translation of the 1913 Michaelis–Menten paper. Biochemistry. 2011;50(39):8264–9) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kholodenko BN, Hancock JF, Kolch W. Signalling ballet in space and time. Nat Rev Mol Cell Biol 2010. June;11(6):414–26. 10.1038/nrm2901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ventura AC, Jiang P, Van Wassenhove L, Del Vecchio D, Merajver SD, Ninfa AJ. Signaling properties of a covalent modification cycle are altered by a downstream target. Proc Natl Acad Sci U S A. 2010/05/17. 2010. June 1;107(22):10032–7. 10.1073/pnas.0913815107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ventura AC, Sepulchre J-A, Merajver SD. A hidden feedback in signaling cascades is revealed. PLoS Comput Biol. 2008. March;4(3):e1000041. 10.1371/journal.pcbi.1000041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Del Vecchio D, Ninfa AJ, Sontag ED. Modular cell biology: retroactivity and insulation. Mol Syst Biol 2008/02/12. 2008;4:161. 10.1038/msb4100204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Catozzi S, Di-Bella JP, Ventura AC, Sepulchre J-A. Signaling cascades transmit information downstream and upstream but unlikely simultaneously. BMC Syst Biol. 2016;10(1):84. 10.1186/s12918-016-0303-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Grunberg TW, Del Vecchio D. Modular analysis and design of biological circuits. Curr Opin Biotechnol. 2020;63:41–7. 10.1016/j.copbio.2019.11.015 [DOI] [PubMed] [Google Scholar]
  • 29.Ossareh HR, Ventura AC, Merajver SD, Del Vecchio D. Long signaling cascades tend to attenuate retroactivity. Biophys J 2011. April 6;100(7):1617–26. 10.1016/j.bpj.2011.02.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ventura AC, Jackson TL, Merajver SD. On the role of cell signaling models in cancer research. Cancer Res. 2009;69(2):400–2. 10.1158/0008-5472.CAN-08-4422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jiang P, Ventura AC, Sontag ED, Merajver SD, Ninfa AJ, Del Vecchio D. Load-induced modulation of signal transduction networks. Sci Signal. 2011;4(194):ra67–ra67. 10.1126/scisignal.2002152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Jayanthi S, Nilgiriwala KS, Del Vecchio D. Retroactivity controls the temporal dynamics of gene transcription. ACS Synth Biol. 2013;2(8):431–41. 10.1021/sb300098w [DOI] [PubMed] [Google Scholar]
  • 33.Brewster RC, Weinert FM, Garcia HG, Song D, Rydenfelt M, Phillips R. The transcription factor titration effect dictates level of gene expression. Cell. 2014;156(6):1312–23. 10.1016/j.cell.2014.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kim Y, Coppey M, Grossman R, Ajuria L, Jiménez G, Paroush Z, et al. MAPK substrate competition integrates patterning signals in the Drosophila embryo. Curr Biol. 2010. March 9;20(5):446–51. 10.1016/j.cub.2010.01.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kim Y, Paroush Z, Nairz K, Hafen E, Jiménez G, Shvartsman SY. Substrate-dependent control of MAPK phosphorylation in vivo. Mol Syst Biol 2011. February 1;7:467. 10.1038/msb.2010.121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Puskas J.E., Kantor J., Shrikande G., 2017. Reaction engineering with enzymes: A relatively uncharted territory. AIChE J. 63,266–272. [Google Scholar]
  • 37.Levine J, Kueh HY, Mirny LA. Intrinsic fluctuations, robustness and tunability in signalling. Biophys J. 2007. 92, 4473–4481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Birtwistle M, Rauch J, Kiyatkin A, Aksamitine E, Doberzynski M, Hoek J, et al. Emergence of bimodal cell population responses from the interplay between analog single-cell signaling and protein expression noise. BMC Syst Biol. 2012. 6, 109. 10.1186/1752-0509-6-109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Jr Ferrell. JE, Machleder EN. The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science. 1998. 280, 895–898. [DOI] [PubMed] [Google Scholar]
  • 40.Straube R. Operating regimes of covalent modification cycles at high enzyme concentrations. J Theor Biol. 2017;431:39–48. 10.1016/j.jtbi.2017.08.006 [DOI] [PubMed] [Google Scholar]
  • 41.Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 2016. February 11;164(4):780–91. 10.1016/j.cell.2016.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zhou X.X., Fan L.Z., Li P., Shen K., Lin M.Z., Optical control of cell signaling by single-chain photoswitchable kinases. Science. 2017. 355, 836–842. 10.1126/science.aah3605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Mathworks, Inc. 2017. Weblink: http://in.mathworks.com/help/optim/ug/fmincon.html

Decision Letter 0

Christopher Rao

9 Feb 2021

PONE-D-20-35461

Retroactivity induced operating regime transition in a phosphorylation-dephosphorylation reaction cycle

PLOS ONE

Dear Dr. Viswanathan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 22 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Christopher V. Rao

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following in the Acknowledgments Section of your manuscript:

"We thank Department of Science and Technology, 390 Government of India for funding this study."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study presented by Parundekar and Viswanathan investigates how sequestering the substrate or product of a phosphorylation/dephosphorylation cycle can shape the steady-state dose-response curve of the cycle, where the “dose” or input of the system corresponds to the concentration of the kinase catalyzing the phosphorylation. As a starting point, the authors derived an analytical expression for the steady-state phosphorylation of a simple model of phosphorylation/dephosphorylation including the sequestration of the substrate and/or product. The model output is studied by applying a classification scheme introduced by Gomez-Uribe et al. which categorizes dose-response curves into one of four characteristic operating-regimes such as hyperbolic or ultrasensitive. The main finding of the study is that protein sequestration can alter the shape of the dose-response curve and that by modifying the strength of sequestration, a cell could cause the dose-response curve of the phosphorylation/dephosphorylation cycle to shift from one operating regime into a different one.

Phosphorylation/dephosphorylation cycles are important and ubiqituous signaling motifs and the presented findings are interesting. Although the chosen approach is in principle rigorous, the current implementation seems to be flawed at several points. Please see the list of major and minor concerns below, many of which should be easy to address.

Major issues:

(1) Most importantly: the derivation of equation [5] presented by the authors is, I believe, incorrect and some of the definitions for composite quantities provided by the authors are not consistent with equation [5]. Please refer to the attached document for further details and see whether you agree with my analysis. Generally, I think the derivation presented in appendix 1 would benefit from showing the full mass-action reaction scheme and smaller steps in the derivation

(2) The authors introduce the four operating regimes as defined by Gomez-Uribe with almost no explanation. Since many biologists or biochemists are not even familiar with the term ultrasensitivity, I strongly suggest to add a bit more detail here: How are these regimes defined? How do their dose-response curves look like? (A small figure similar to Fig 2 in Gomez-Uribe et al. 2007 would be helpful.) What are their properties, how does this translate into different signaling functions and why is this biologically important?

(3) It is not clear to me how the regime identification procedure based on relative distance/error can avoid misclassification. For instance, would a TH curve not be misclassified as ultrasensitive if the threshold coincides with the EC50 of the nominal US profile? (see attached picture: TH* is closer to US than to TH). Also, why is the area of the regimes (especially TH) in the K1 vs K2 plot so different from Gomez-Uribe et al. 2007?

(4) Since a regime transition due to sequestration has already been described before (Ventura et al.), the manuscript could benefit from extending the scope a little. Given that Gomez-Uribe et al. 2007 found the different regimes to influence low-pass filtering properties, I suspect studying the influence of k_on or k_off of the sequestration reactions on cycle dynamics and low-pass filtering could offer interesting insights which may increase the impact of the study (e.g. simple numerical analysis with the mass-action model).

Minor issues:

(1) Abstract, p2. Line 35: I don’t think “sequestration strength of 0.3” is a helpful description for most readers. A qualitative description would be more helpful.

(2) The expression “PdPC” seems a bit cumbersome to me. Since the studied motif not only applies to phosphorylation/dephosphorylation cycles but also to other PTMs or to GTPase cycles, I find it more appropriate to use a more common and general expression such as activation/inactivation cycle, PTM cycle, futile cycle …

(3) I don’t understand how increasing the input dose (e.g. kinase concentration) of a cycle can itself induce a regime shift? (p.4, line 77)

(4) p.5, line 118-119: the authors speak of a QSSA for MS1 and MS2, yet I see no use of MS1 or MS2 QSSA in the whole paper

(5) Where does equation [7] come from? From the cited references or from the authors’ study solved manually/by computer algebra system?

(6) Figure 2: The plot of the nominal regime ST almost overlaps with the Y axis and upper border of the figure. The characteristic feature of the ST regime (linear increase until saturation) cannot be identified here! Better rescale the axis or use log(X) axis.

(7) The rate balance figures (figure 4 and supplementary figures) are quite crowded and it would help to use color gradient lines (whose numerical values are given in a legend) instead of all the arrows and values. For figure 4 in particular, it would be very helpful to also show 3D dose-response plots visualising the regime transitions (Z-axis = m, X-axis = e_t, Y-axis = α or λ). These are often more intuitive to understand than rate balance plots.

(8) Sections 3.3.1 and 3.3.2 are largely descriptive of the figures and could be shortened by focussing more on the overall effect of changing α or λ at a nominal operating point and by moving parameter values to the figure legends.

Reviewer #2: In this paper, the authors investigate the operating regimes of a signaling cycle consisting of a protein that can be in an inactive or active form: the protein is activated and deactivated by two enzymatic species, a kinase and phosphatase, respectively. The main novelty introduced in this paper is the presence of a downstream load on the protein (on both the forms) determining retroactivity. The authors characterize the effect of retroactivity on the input-output relationship (i.e. operating regime) of the cycle, where the input is the kinase concentration and the output the active form of the protein (normalized with respect to its total concentration). Moreover, they find that increasing retroactivity strength can trigger five possible regime transitions: for four possible transitions, they show that the modulation of the saturation levels of the enzymatic reactions by increasing retroactivity is the main reason for the operating regime transitions.

The paper is interesting. I have the following comments/questions.

The quasi-steady-state approximation (QSSA) is employed to study the system defined by biochemical reactions [1-4] and get Eq. [5]. However, the full ODE model should also be implemented and simulated: the corresponding steady-state results should be compared with those obtained by exploiting QSSA in order to verify and validate this approximation.

About Fig. 2, it would be better to use inserts in panels A and B showing a zoom-in of the active form of protein vs the kinase concentration (e_t) on lower e_t values.

Moreover, be sure to use a small step size for lower e_t values in order to not miss any significant behavior and confirm the obtained results.

From this study, it seems to emerge that the ultrasensitive threshold (i.e. EC50) can be modulated by retroactivity. Could the authors give more details, in particular, by quantifying the modulation?

Could the authors give more details about the criterion defined by Eq. 8?

For each figure, the caption should be more exhaustive.

I would recommend to the authors to improve understanding/readability of the manuscript to provide more details in the figure captions.

Could the authors explain better the results reported in Section 3.3 and shown in Fig.4? Is the dotted line reported in each panel representing the transition from a regime to another (from U to TH for panels A and B and from U to ST for panels C and D)? Could the authors explain better in the text how retroactivity strength modulates the saturation levels of the enzymatic reactions?

Instead of summarizing the results obtained for the other transitions at the end of Section 3.3.2, it would be better to add another subsection and provide more details of the results reported in the supplementary text.

Minor comments

In Section 2, when the enzyme concentrations e_t and p_t are defined, it should be specified that these concentrations represent the total concentrations of E and P, respectively, in the unbounded and bounded forms.

Please check punctuation, as line 210 (it is missing a full stop).

Define the abbreviations (as rhs) at first occurrence.

Line 273, it should be et=3000 nM in Rp.

Line 275, it should be lambda=0 in Rp.

Line 278, falls instead of fall.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Daniel Koch

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Issues derivation of equation 5.pdf

Attachment

Submitted filename: RegimeClassification.jpg

PLoS One. 2021 Apr 30;16(4):e0250830. doi: 10.1371/journal.pone.0250830.r002

Author response to Decision Letter 0


21 Mar 2021

Response to Editor’s and reviewers’ comments

We thank the Editor and the two reviewers for detailed comments and suggestions on the manuscript. These suggestions have indeed helped improve the manuscript significantly. We present below a detailed point-wise response to the comments.

I. Response to comments by Editor

E1: PONE-D-20-35461

Retroactivity induced operating regime transition in a phosphorylation-dephosphorylation reaction cycle PLOS ONE Dear Dr. Viswanathan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 22 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Response: We thank the Editor for considering the manuscript and we now submit a revised version of the manuscript incorporating various suggestions made by the reviewers.

E2: Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Response: We now submit these three documents.

E3: If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

Response: We have now included the revised statement (in the response to comment E5 below) in the cover letter. Further, we have adhered to the guidelines corresponding to the figure files.

E4: When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: We have now ensured that the manuscript meets the specified style.

E5: 2.Thank you for stating the following in the Acknowledgments Section of your manuscript:

"We thank Department of Science and Technology, 390 Government of India for funding this study."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: We have now deleted the statement regarding the funding information from the Acknowledgements section. We would like the funding statement to be modified as

"This study was supported by Science and Engineering Research Board, Department of Science and Technology, Government of India (MTR/2020/000589 and CRG/2020/002672) for funding this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

We have now specified this modified funding statement in the cover letter with a request to amend the statements in the relevant places.

II. Response to Reviewers' comments

Q1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Response: We thank the reviewer for the opinion. Based on the comments from the reviewers, we have now revised the manuscript (and the supplementary material) extensively to tie tightly the conclusions drawn to the results presented in various figures.

Q2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Response: N/A

Q3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Response: We thank the reviewers for this observation.

Q4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Response: We thank the reviewer for highlighting in their comments various aspects that could be improved. We have now incorporated these and have improved clarity of presentation of the results, of conclusions drawn and of the discussions made in several sections. We have further fixed several grammatical, style-related, and typographical errors in the entire manuscript. We believe these changes would address the above concerns.

Q5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Response: We present below point-wise response to the comments and also refer to the manuscript wherever relevant to highlight the changes incorporated.

R1.1 Reviewer #1: The study presented by Parundekar and Viswanathan investigates how sequestering the substrate or product of a phosphorylation/dephosphorylation cycle can shape the steady-state dose-response curve of the cycle, where the “dose” or input of the system corresponds to the concentration of the kinase catalyzing the phosphorylation. As a starting point, the authors derived an analytical expression for the steady-state phosphorylation of a simple model of phosphorylation/dephosphorylation including the sequestration of the substrate and/or product. The model output is studied by applying a classification scheme introduced by Gomez-Uribe et al. which categorizes dose-response curves into one of four characteristic operating-regimes such as hyperbolic or ultrasensitive. The main finding of the study is that protein sequestration can alter the shape of the dose-response curve and that by modifying the strength of sequestration, a cell could cause the dose-response curve of the phosphorylation/dephosphorylation cycle to shift from one operating regime into a different one.

Phosphorylation/dephosphorylation cycles are important and ubiqituous signaling motifs and the presented findings are interesting.

Response: We thank the reviewer for the observations about the manuscript and valuable comments.

R1.2: Although the chosen approach is in principle rigorous, the current implementation seems to be flawed at several points. Please see the list of major and minor concerns below, many of which should be easy to address.

Response: We thank the reviewer for noting the rigor adopted in the work. We thank the reviewer for these comments and we have addressed these and incorporated them in detail in the revised version of the manuscript.

R1.3: Major issues:

(1) Most importantly: the derivation of equation [5] presented by the authors is, I believe, incorrect and some of the definitions for composite quantities provided by the authors are not consistent with equation [5]. Please refer to the attached document for further details and see whether you agree with my analysis. Generally, I think the derivation presented in appendix 1 would benefit from showing the full mass-action reaction scheme and smaller steps in the derivation

Response: We thank the reviewer for these observations, for concerns regarding the model employed in the study, and also the derivations attached. We agree that we did not present some of the underlying assumptions made and the derivation of the quasi-steady state approximation (QSSA) model. Specifically, we did not explicitly present the full ODE model. We believe these lacunae have caused the lack of clarity. As has also been suggested by Reviewer 2 in comment R2.2, we now present in Appendix I, in pages 22-23, lines (510-537) in the revised manuscript a detailed full model with the assumptions made. In pages 23-24, lines (538-553) in the revised manuscript, we present a detailed derivation of the QSSA model with intermediate steps. We also present definitions of the each of the quantities used. Subsequently, in

R1.4: (2) The authors introduce the four operating regimes as defined by Gomez-Uribe with almost no explanation. Since many biologists or biochemists are not even familiar with the term ultrasensitivity, I strongly suggest to add a bit more detail here: How are these regimes defined? How do their dose-response curves look like? (A small figure similar to Fig 2 in Gomez-Uribe et al. 2007 would be helpful.) What are their properties, how does this translate into different signaling functions and why is this biologically important?

Response: We thank the reviewer for the suggestion to include a figure on the dose-response curves and the different operating regimes. We have now included in Fig. 2 representative dose-response curves of the four operating regimes. We have explicitly stated in Table 1 the conditions employed for drawing these curves and have discussed the associated definitions in detail in page 7, in lines (159-171)in the revised manuscript. Further, in lines (172-179) in the revised manuscript, we have discussed briefly the properties and potential biological relevance of the operating regimes along with citations.

R1.5: (3) It is not clear to me how the regime identification procedure based on relative distance/error can avoid misclassification. For instance, would a TH curve not be misclassified as ultrasensitive if the threshold coincides with the EC50 of the nominal US profile? (see attached picture: TH* is closer to US than to TH).

Response: We thank the reviewer for bringing to our attention this possible lack of clarity. As shown in Fig. 4, the boundaries obtained using the metric adopted show that a clear separation between all regimes except Hyperbolic (H) and Ultrasensitive (U) which have a marginal overlap. We compare in Fig. R1.1 below the EC50 distribution of all the dose-response curves that were classified into the Ultrasensitive (U) and Threshold-Hyperbolic (TH) regimes. The distribution clearly shows that the dose-response curve that we classify into U regime cannot have an EC50 beyond that of those in TH regime in the parameter range considered. Moreover, since the metric in Eq. 8 (page 11, line 242 in the revised manuscript) uses a self-learned scaling and that ensures that misclassification can be predominantly circumvented. Note that the self-learned scaling is system parameter independent, unlike the metric adopted by Gomez-Uribe et al [Gomez-Uribe et al., PLoS Comp Biol., 2007], due to which the operating regimes reported had overlap among all the regimes. We have highlighted and discussed the importance of the metric used in this study in page 11, lines 245-251 in the revised manuscript.

<<figure in the attached 'Response to reviewers.docx' file>>

Figure R1.1: Boxplot showing the distribution of the EC50 for the dose-response curves in the Ultrasensitive and Threshold Hyperbolic regimes.

R1.6: Also, why is the area of the regimes (especially TH) in the K1 vs K2 plot so different from Gomez-Uribe et al. 2007?

Response: K1 vs K2 plot presented in Fig. 4 is different from Gomez-Uribe et al. because their model employs total quasi-steady state approximation which permits validity of the reduced model for a larger range of parameters. Further, their metric uses total substrate concentration as a metric and therefore their classification is strongly system parameter dependent.

R1.7: (4) Since a regime transition due to sequestration has already been described before (Ventura et al.), the manuscript could benefit from extending the scope a little. Given that Gomez-Uribe et al. 2007 found the different regimes to influence low-pass filtering properties, I suspect studying the influence of k_on or k_off of the sequestration reactions on cycle dynamics and low-pass filtering could offer interesting insights which may increase the impact of the study (e.g. simple numerical analysis with the mass-action model).

Response: The reviewer is correct in observing that Ventura et al. has reported modulation of dose-response curves by sequestration. The Hill coefficient and S50, an alternative for EC50 pattern were used to make an observation of a couple of transitions via a few examples. However, this approach does not offer any insight into underlying causal mechanism governing such a modulation. Moreover, the systematic transition from different types of response are not considered either.

The goal of this study is to systematically characterize operating regimes in the presence of sequestration, identify all possible transitions and the specific causal mechanisms governing these. This is stated in the introduction in the last paragraph in page 4 (lines 97-104) in the revised manuscript and also in line 216, page 10 in the revised manuscript. Different responses of the enzymatic futile cycle is governed by the levels of the saturation or unsaturation of the two enzymatic reactions. We contrast a dose-response curve with the nominal curves, which incorporates the saturated and unsaturated states of the enzymes, using a metric and characterize them systematically. To the best of our knowledge, our study is the first to systematically characterize all four operating regimes of a futile cycle in the presence of retroactivity (Fig. 4 of the revised manuscript), and also the 12 transitions between them. Further we identify the precise causal mechanism governing retroactivity driven regime transition (Figs. 5 and 6)

We agree with the reviewer that effect of sequestration parameters on the dynamics and low-pass filtering properties are indeed important and will offer new insights into the dynamical behaviour of the enzymatic futile cycle. However, we would like to restrict this study to only the steady-state response of the cycle and we think analysing the dynamical behaviour is indeed a logical extension of this study which we will consider in a separate manuscript in the future.

R1.8: Minor issues: (1) Abstract, p2. Line 35: I don’t think “sequestration strength of 0.3” is a helpful description for most readers. A qualitative description would be more helpful.

Response: We thank the reviewer for bring this to our attention. Both in abstract and also in section 3, page 13, lines 298-303, we have now provided a logical interpretation of the “sequestration strength of 0.3” which we believe would help readers appreciate the importance of it better.

R1.9: (2) The expression “PdPC” seems a bit cumbersome to me. Since the studied motif not only applies to phosphorylation/dephosphorylation cycles but also to other PTMs or to GTPase cycles, I find it more appropriate to use a more common and general expression such as activation/inactivation cycle, PTM cycle, futile cycle …

Response: We have now replaced PdPC with ‘enzymatic futile cycle’ everywhere in the manuscript, including the title.

R1.10: (3) I don’t understand how increasing the input dose (e.g. kinase concentration) of a cycle can itself induce a regime shift? (p.4, line 77)

Response: We thank the reviewer to bringing to our attention this lack of clarity. The input here refers to the stimulus that triggers the cells and thereby activates the MAPK cascade. We inadvertently referred to this as “dose-strength dependent”. For better clarity and capture of the findings reported in ref. [21], we have now split and re-phrased the entire sentence into two sentences in pages 3-4, lines 75-79.

R1.11: (4) p.5, line 118-119: the authors speak of a QSSA for MS1 and MS2, yet I see no use of MS1 or MS2 QSSA in the whole paper

Response: We agree with the reviewer. We have now re-phrased the sentence in page 6, line124-125.

R1.12: (5) Where does equation [7] come from? From the cited references or from the authors’ study solved manually/by computer algebra system?

Response: To get Eq. (7), we solved the quadratic equation obtained by setting the lhs to zero in Eq. (5). We have now explicitly stated so in page 6, lines145-146.

R1.13: (6) Figure 2: The plot of the nominal regime ST almost overlaps with the Y axis and upper border of the figure. The characteristic feature of the ST regime (linear increase until saturation) cannot be identified here! Better rescale the axis or use log(X) axis.

Response: We agree with the reviewer that the linear increase property of the ST regime was unclear in Fig. 2 of the first submitted version of the manuscript. In the revised version of the manuscript, in Fig. 3 -- previously Fig. 2 --- we have provided a zoomed version of both the plots to show the linear increase until saturation for the nominal profile of ST. Morever, we have described the same in the caption for the figure.

R1.14: (7) The rate balance figures (figure 4 and supplementary figures) are quite crowded and it would help to use color gradient lines (whose numerical values are given in a legend) instead of all the arrows and values. For figure 4 in particular, it would be very helpful to also show 3D dose-response plots visualising the regime transitions (Z-axis = m, X-axis = e_t, Y-axis = α or λ). These are often more intuitive to understand than rate balance plots.

Response: We agree with the reviewer that Fig. 4 and the last two figures in Text S1 were quite crowded. As suggested, we have now provided a colorbar (with numerical values specifying the legend) for the each of the panels in Fig. 5 and also in the last two figures in Text S1. Moreover, we have also included an additional figure for every panel in Figure 5 capturing the dependence of dose-response curves on the retroactivity strengths used. Moreover, such a plot corresponding to the last two figures in Text S1 is now presented in Fig 6, which are discussed in a new sub-section 3.3.4, as suggested by Reviewer 2 in R2.9.

Further, in order to help a reader understand the results from the rate-balance plots better and correlate the inferences with the dose-response curves and sensitivity, we have extensively rephrased the corresponding description of results in sub-sections 3.3.1-3.3.4.

R1.15: (8) Sections 3.3.1 and 3.3.2 are largely descriptive of the figures and could be shortened by focussing more on the overall effect of changing α or λ at a nominal operating point and by moving parameter values to the figure legends.

Response: We have now re-written the entire section and wherever possible, we have removed redundant descriptions and focussed on the overall effects captured by the figures. We have also included helpful descriptions and some parameter values in the figure captions.

R2.1 Reviewer #2: In this paper, the authors investigate the operating regimes of a signaling cycle consisting of a protein that can be in an inactive or active form: the protein is activated and deactivated by two enzymatic species, a kinase and phosphatase, respectively. The main novelty introduced in this paper is the presence of a downstream load on the protein (on both the forms) determining retroactivity. The authors characterize the effect of retroactivity on the input-output relationship (i.e. operating regime) of the cycle, where the input is the kinase concentration and the output the active form of the protein (normalized with respect to its total concentration). Moreover, they find that increasing retroactivity strength can trigger five possible regime transitions: for four possible transitions, they show that the modulation of the saturation levels of the enzymatic reactions by increasing retroactivity is the main reason for the operating regime transitions.

The paper is interesting. I have the following comments/questions.

Response: We thank the reviewer for the observations and the comments.

R2.2: The quasi-steady-state approximation (QSSA) is employed to study the system defined by biochemical reactions [1-4] and get Eq. [5]. However, the full ODE model should also be implemented and simulated: the corresponding steady-state results should be compared with those obtained by exploiting QSSA in order to verify and validate this approximation.

Response: We thank the reviewer for this suggestion. In Text S1.1, we present a detailed solution of the full ODE model at steady-state conditions. The full ODE model is presented in Appendix I in the revised version of the manuscript as suggested by Reviewer 1 in R1.3. The solution of the full model matches with the solution of the QSSA model in Eq. (5) in the manuscript.

R2.3: About Fig. 2, it would be better to use inserts in panels A and B showing a zoom-in of the active form of protein vs the kinase concentration (e_t) on lower e_t values.

Moreover, be sure to use a small step size for lower e_t values in order to not miss any significant behavior and confirm the obtained results.

Response: We thank the reviewer to bring this point to our attention. In the revised manuscript, we have now incorporated a zoomed version of the two sub-figures as inset in Fig. 3 (which was Fig. 2 in the version submitted earlier). The zoomed version now shows the linear increase property of the ST nominal profile.

R2.4: From this study, it seems to emerge that the ultrasensitive threshold (i.e. EC50) can be modulated by retroactivity. Could the authors give more details, in particular, by quantifying the modulation?

Response: We thank the reviewer for this suggestion of quantifying the EC50 in the Ultrasensitive regime. We capture the S50 (Eq. 11 in the revised manuscript), which was used to estimate the EC50, for different dose-response curves at different retroactivity strengths. We now present the effect of retroactivity strength on the EC50 in Fig. S1.3 in the Suppl Text S1. We briefly discuss this effect in sub-sections 3.3.1 and 3.3.2 in page 14, lines 332-334 and in page 17, 386-387.

R2.5: Could the authors give more details about the criterion defined by Eq. 8?

Response: We thank the reviewer for suggesting to provide more details on Eq. 8. We now present a detailed discussion on the origin and basis for the criterion and also the advantages of the same in page 11, lines 243-251 in the revised version of the manuscript.

R2.6: For each figure, the caption should be more exhaustive.

I would recommend to the authors to improve understanding/readability of the manuscript to provide more details in the figure captions.

Response: We thank the reviewer for this suggestion. We agree that certain details are missing in the figure captions. We have now revised the captions all the existing and new figures both in the main text and supplementary information. We provide detailed description and details in each of the captions.

R2.7:L Could the authors explain better the results reported in Section 3.3 and shown in Fig.4?

Response: We thank the reviewer for this suggestion. We have now re-written the entire subsection 3.3 corresponding to Fig 5 (which is Fig. 4 in the originally submitted manuscript) with better explanation. We have also introduced a dose-response curves figure corresponding to each of the transitions to explain the results better, as suggested by reviewer 1 in R1.14.

R2.8: Is the dotted line reported in each panel representing the transition from a regime to another (from U to TH for panels A and B and from U to ST for panels C and D)?

Response: We thank the reviewer for bringing this lack of clarity to our attention. Yes, dotted line represents the transition. We have now explicitly stated that dotted line corresponds to the transition in the figure caption, in page 16, line 380 in the revised version of the manuscript.

R2.9: Could the authors explain better in the text how retroactivity strength modulates the saturation levels of the enzymatic reactions?

Response: We thank the reviewer for this concern. We have now explained in the revised manuscript in page 15, in the lines 348-352: “The nature of an enzymatic reaction being saturated, that is, all enzymes bound to its substrate, is specified by the range of m̅ for which the corresponding rate does not change significantly. Therefore a sufficient proportional increase in K̅1(λ) due to λ can lead to Rp exhibiting a linear dependence on m̅ in a certain range. The nature of the phosphorylation reaction is unsaturated in this range of m̅.”

R2.10: Instead of summarizing the results obtained for the other transitions at the end of Section 3.3.2, it would be better to add another subsection and provide more details of the results reported in the supplementary text.

Response: We thank the reviewer for this suggestion. We have now moved the H to ST transition into Fig. 5 (previously Fig 4). Further, as suggested by Reviewer 1 in R1.14, we have introduced the dose-response curves in Figs. 5A, 5D, 5G and in Fig. 6 corresponding to the five transitions explained. We have now re-written the sub-sections 3.3.1 and 3.3.2 and also introduced a new sections 3.3.3 and 3.3.4. In these four sub-sections, we analyse and identify the causal mechanisms governing these 5 transitions.

R2.11: Minor comments In Section 2, when the enzyme concentrations e_t and p_t are defined, it should be specified that these concentrations represent the total concentrations of E and P, respectively, in the unbounded and bounded forms.

Response: We thank the reviewer for bringing this issue to our attention. We have now include the word “total” in page 6, line130-131.

R2.12: Please check punctuation, as line 210 (it is missing a full stop).

Response: We have now thoroughly checked the entire manuscript and fixed several grammatical and typographical errors.

R2.13: Define the abbreviations (as rhs) at first occurrence.

Response: We have now defined abbreviations at first occurrence. For example, “right hand side” in page 6, line 142.

R2.14: Line 273, it should be et=3000 nM in Rp.

Response: We have incorporated this correction in line 428, page 18 in the revised manuscript.

R2.15: Line 275, it should be lambda=0 in Rp.

Response: We have incorporated this correction in line 355, page 15 in the revised manuscript. We have now thoroughly checked the numbers and symbols and their consistency throughout the revised manuscript.

R2.16: Line 278, falls instead of fall.

Response: We have re-phrased this sentence. Further we have thoroughly revised the manuscript and fixed several typographical and grammatical errors.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Daniel Koch

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Christopher Rao

15 Apr 2021

Retroactivity induced operating regime transition in an enzymatic futile cycle

PONE-D-20-35461R1

Dear Dr. Viswanathan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Christopher Rao

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In my view, the authors have sufficiently addressed the raised issues and the overall clarity of the presentation and figures improved notably. A last comment: I might be wrong since I'm not a native speaker, but I feel there are still some language issues, e.g. with the first sentence of the abstract: "Activated phosphorylation-dephosphorylation biochemical reaction cycle is a class of enzymatic futile cycles." Should it not be "THE activated phosphorylation-dephosphorylation biochemical reaction cycle (...)" or "Activated phosphorylation-dephosphorylation biochemical reaction cycleS ARE (...)"?

However, I see no reason to further delay publication of the authors' interesting findings and trust they will give the manuscript another round of proof-reading before publication.

Reviewer #2: The authors have addressed all my previous comments.

I have few minor comments:

Line 143 of the 'Revised Manuscript with Track Changes', please define K1 and K2.

Line 624, it should be PMp.

For fig 3 (and for similar figs), please add in the caption the K1_bar and K2_bar values for obtaining the nominal U profile (blu dotted curve, shown also in fig 2) as done for the yellow curve.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Daniel Koch

Reviewer #2: No

Acceptance letter

Christopher Rao

22 Apr 2021

PONE-D-20-35461R1

Retroactivity induced operating regime transition in an enzymatic futile cycle

Dear Dr. Viswanathan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Christopher Rao

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text

    S1.1- Steady-state solution of the full model. S1.2- Dose-response curve transition from Signal-Transducing to Hyperbolic regime induced by substrate retroactivity. S1.3- Minimum retroactivity strength required to transition from one regime to another. S1.4- Effect of retroactivity strength on EC50 during different regime transitions. S1.5-Sensitivity and rate balance analysis to investigate retroactivity induced ST to H and TH to H regime transitions.

    (PDF)

    S1 Graphical abstract

    (TIFF)

    S1 Appendix. Derivation of the mathematical kinetic model.

    (DOCX)

    S2 Appendix. Sensitivity of steady-state level to retroactivity strength.

    (DOCX)

    Attachment

    Submitted filename: Issues derivation of equation 5.pdf

    Attachment

    Submitted filename: RegimeClassification.jpg

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES